Source:http://linkedlifedata.com/resource/pubmed/id/19249389
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-4-10
|
| pubmed:abstractText |
Cisplatin is broadly used clinically as an anticancer drug. Despite its significant anticancer activity, cisplatin-induced nephrotoxicity and myelosuppression limit its use. MD-Fraction is glucan purified from maitake (Grifola frondosa), which has beta-1, 6-main chain with beta-1, 3-branches, has been reported to exhibit antitumor and antimetastatic activities by enhancing the immune system. In this study, we demonstrate that MD-Fraction in combination with cisplatin significantly enhanced antitumor and antimetastatic activity compared to cisplatin alone. MD-Fraction reduced decreases in body weight, spleen weight and the number of immunocompetent cells such as macrophages, DCs and NK cells in cisplatin-treated mice. MD-Fraction also induced IL-12p70 production by splenocytes, resulting in increased NK cell activity in cisplatin-treated mice. MD-Fraction significantly increased the mRNA expression of GM-CSF, G-CSF, M-CSF, IFN-gamma, IL-12 p40 in splenocytes and reduced the decrease in the number of CFU-GM colonies in cisplatin-treated bone marrow. These facts suggest that MD-Fraction can reduce cisplatin-induced myelosuppression. Moreover, treatment with MD-Fraction significantly reduced cisplatin-induced nephrotoxicity accompanied by increases in serum creatinine level, necrosis and apoptosis of renal tubular cells. These results suggest that MD-Fraction in combination with cisplatin cannot only enhance antitumor and antimentastatic acitivity, but also reduce cisplatin-induced myelotoxicity and nephrotoxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Fungal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Glucans
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1878-1705
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
620-6
|
| pubmed:meshHeading |
pubmed-meshheading:19249389-Animals,
pubmed-meshheading:19249389-Antigens, Fungal,
pubmed-meshheading:19249389-Antineoplastic Agents,
pubmed-meshheading:19249389-Apoptosis,
pubmed-meshheading:19249389-Bone Marrow,
pubmed-meshheading:19249389-Cell Line, Tumor,
pubmed-meshheading:19249389-Cisplatin,
pubmed-meshheading:19249389-Colony-Forming Units Assay,
pubmed-meshheading:19249389-Colorectal Neoplasms,
pubmed-meshheading:19249389-Creatinine,
pubmed-meshheading:19249389-Drug Synergism,
pubmed-meshheading:19249389-Female,
pubmed-meshheading:19249389-Grifola,
pubmed-meshheading:19249389-Interferon-gamma,
pubmed-meshheading:19249389-Interleukin-12,
pubmed-meshheading:19249389-Kidney,
pubmed-meshheading:19249389-Killer Cells, Natural,
pubmed-meshheading:19249389-Lung Neoplasms,
pubmed-meshheading:19249389-Lymphocyte Activation,
pubmed-meshheading:19249389-Mice,
pubmed-meshheading:19249389-Mice, Inbred BALB C,
pubmed-meshheading:19249389-Neoplasm Transplantation,
pubmed-meshheading:19249389-Organ Size,
pubmed-meshheading:19249389-Phytotherapy,
pubmed-meshheading:19249389-beta-Glucans
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice.
|
| pubmed:affiliation |
Department of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Japan. micro-s@kobepharma-u.ac.jp
|
| pubmed:publicationType |
Journal Article
|